15 pre-measured single-serve sachets no scoop, no measuring, no mess
Mujdat Zeybel, MD, NIHR Nottingham Biomedical Research Centre This study demonstrated CMCS supplementation significantly decreased liver fat, improved liver function, and decreased liver inflammation in NAFLD patients, suggesting CMCS may be an effective therapeutic strategy for NAFLD, No drugs have been approved to treat NAFLD, and effective treatment options with long-term safety are urgently required. The combined metabolic cofactor supplementation (CMCS) regimen developed by the Nottingham group and used in this trial consists of: 1g nicotinamide riboside (NR), which raises mitochondrial NAD+ levels, and boosts fat metabolism 3.73g L-carnitine tartrate, which promotes transport of fat into the mitochondria 12.35g L-serine, which increases glutathione synthesis 2.55g N acetyl-L-cysteine (NAC), which also promotes glutathione production and reduces oxidative stress A total of 31 patients with MRI-confirmed non-alcoholic steatosis were randomized to either placebo (N=11) or the CMCS combination (N= 20)
D.HallT
T., Malliou, V
Trusted by patients
However, the key limitations of existing studies lie in small clinical sample sizes without multicenter validation and unstandardized intervention protocols in animal models, both of which impede clinical translation
